Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BCG 022-BLD 1102 antibody drug conjugate - Beijing Biocytogen

Drug Profile

BCG 022-BLD 1102 antibody drug conjugate - Beijing Biocytogen

Alternative Names: BCG022-BCPT02; BCG022-BLD1102; HER3×MET bispecific antibody-drug conjugate - Beijing Biocytogen

Latest Information Update: 27 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Biocytogen
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 Apr 2024 BCG 022-BCPT 02 antibody drug conjugate - Beijing Biocytogen is available for licensing as of 05 Apr 2024. https://en.biocytogen.com.cn/pipeline.html as of April 2024 (Beijing Biocytogen pipeline, April 2024)
  • 05 Apr 2024 Preclinical trials in Cancer in China (Parenteral) prior to April 2024 (Beijing Biocytogen pipeline, April 2024)
  • 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top